Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy

The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy

Inclusion Criteria:

• Subjects aged >= 18 years
• Females of child bearing potential must have a negative urine pregnancy test prior to entry into the study
• Patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral anticoagulation
• Signed written informed consent by the subject, or if the subject is unable to do so, consent will be sought from their family member, or a trusted person nominated by the subject or the legal representative

Exclusion Criteria:

• Uncontrolled bleeding
• Severe hepatic impairment (Child-Pugh Class C)
• Hypersensitivity to argatroban or to any of the excipients (sorbitol and ethanol)
• Pregnancy (exclusion by routine urine test)
• Lactating woman